Addiction treatment in the United States has long been defined by relapse, revolving-door admissions, and outdated clinical models that struggle to address the Addiction treatment in the United States has long been defined by relapse, revolving-door admissions, and outdated clinical models that struggle to address the

Inside the Future of Addiction Recovery: How Dr. Austin Harris Is Transforming Treatment with an 80% Success Rate

Addiction treatment in the United States has long been defined by relapse, revolving-door admissions, and outdated clinical models that struggle to address the complex neurological and emotional roots of substance dependency. But in Los Angeles, a breakthrough program is fundamentally reshaping what recovery can look like—one that merges medical science, advanced neuromodulation, and deep psychological healing with unprecedented results. At the center of this transformation is Dr. Austin Harris, a physician whose innovative protocol is achieving an extraordinary 80% sobriety rate at eight months, compared to the 10% national average for standard inpatient rehabilitation programs.

Developed and directed by Dr. Austin Harris at NeuroRelief Ketamine® & Infusion Therapy in Sherman Oaks, California, this concierge outpatient program represents one of the most significant evolutions in addiction medicine to emerge in decades. The initiative blends cutting-edge infusion therapy, real-time physiological tailoring, and trauma-informed psychological support into a cohesive model that addresses addiction as both a neurobiological and emotional condition. What results is a comprehensive treatment pipeline that not only facilitates detoxification, but repairs the very neural pathways that have been hijacked by addiction.

A Program Unlike Any Other in the World

According to the initial program announcement, the protocol designed by Dr. Austin Harris is the only one of its kind globally—distinguished by its combination of ketamine therapy, NAD+ infusions, mindful cognitive behavior technique and mindfulness-based training, Certified Integration & Recovery Coaching, and a technological innovation known as the Ascent Sparrow Device. This non-invasive device stimulates the vagus nerve through the skin around the ear, helping significantly reduce withdrawal symptoms, cravings, and the severe physiological effects suffered by individuals detoxing from opiates.

Traditional inpatient programs frequently rely on a linear progression—detox first, often by just weaning to a different, long-acting opiate like suboxone, therapy second. But Dr. Austin Harris challenges this model, citing that high relapse rates reflect a “fundamental flaw” in how conventional treatment conceptualizes addiction. Rather than viewing detox as an isolated physical step, he integrates neurological stabilization, emotional safety, and cognitive clarity right from the beginning, making detox both smoother and more therapeutically meaningful.

The Sparrow Device plays a pivotal role in this shift. By reducing withdrawal-related distress, patients can enter therapeutic work earlier and without the debilitating anxiety, pain, and physical cravings that often trigger relapse before treatment even begins. This neuromodulation technology, paired with infusion-based therapy, creates a stable physiological environment—a cornerstone of the program’s exceptional outcomes.

Ketamine & NAD+: Modern Tools for Brain Repair

Much of the program’s success stems from its medical foundation. Ketamine, once known primarily as an anesthetic, is now widely recognized in mental health and addiction research for its ability to rapidly modulate glutamate receptors, increase neural plasticity, and interrupt harmful neurological patterns. But what differentiates NeuroRelief® is the precision with which ketamine is used.

Each infusion is adjusted in real time by Dr. Austin Harris, whose background in anesthesiology and psychedelic-assisted therapy enables him to tailor dosing based on subtle changes in the patient’s physiology and mental state. This individualized approach avoids the “one-size-fits-all” problem that plagues many ketamine clinics and ensures that each session optimizes neural rewiring and experiential value without overstimulation.

Alongside ketamine, simultaneous NAD+ (nicotinamide adenine dinucleotide) infusions support mitochondrial repair, energy metabolism, and neuro-regeneration. This biochemical boost is particularly important for individuals recovering from chronic substance use, as addiction is known to deplete the brain’s natural healing mechanisms. NAD+ accelerates cognitive restoration, improves mood stability, and helps restore the brain’s reward system—an essential factor in preventing relapse.

Together, ketamine and NAD+ form a synergistic biological foundation upon which long-term recovery is built.

Healing Trauma Without Re-Traumatizing

One of the most groundbreaking aspects of Dr. Austin Harris’ program is its emphasis on trauma-informed care. Addictive behaviors often stem from unresolved emotional wounds, anxiety disorders, and depression. Yet traditional detox-focused programs rarely address these underlying issues early enough to influence lasting change.

The NeuroRelief® model integrates between-infusion integration coaching, a form of guided psychological support that helps patients process insights from their ketamine sessions in a safe, controlled manner. This avoids the risk of re-traumatization while gently allowing long-buried emotional conflicts to resurface and resolve.

Patients are taught mindfulness-based cognitive strategies, breathing techniques, and self-regulation tools, enabling them to replace compulsive patterns with healthier cognitive and emotional habits. By strengthening these neural circuits, the program restores the brain’s natural ability to experience reward—something that chronic addiction often erodes.

A Concierge-Level Model Built for Real Life

Unlike inpatient programs that require patients to uproot their lives, Dr. Austin Harris has intentionally designed an outpatient model that supports daily functioning. Research and clinical observations indicate that learning healthy habits within one’s normal environment drastically improves long-term success rates. The ability to remain connected to work, family, and routine responsibilities reinforces the psychological continuity needed for lasting recovery.

Each patient undergoes a thorough initial evaluation to map out their physiological, emotional, and neurological needs. From there, protocols are dynamically adjusted throughout treatment. This highly personalized approach reflects a “whatever it takes” ethos—one that redefines patient-centered care.

Importantly, Dr. Austin Harris and his team maintain concierge-level accessibility, in real-time, ensuring that no patient ever feels alone in moments of emotional vulnerability or uncertainty. This degree of support is rare in the addiction treatment landscape and contributes significantly to the program’s high success rate.

Addressing Barriers to Access

Historically, advanced addiction treatment has been financially out of reach for many individuals. NeuroRelief® counters this by offering flexible financing options and ensuring that credit scores do not prevent anyone from receiving care. This commitment to accessibility aligns with Dr. Austin Harris’ broader mission: to make scientifically grounded, compassionate treatment available to individuals who may have been failed by traditional programs.

The clinic’s achievements have not gone unnoticed. NeuroRelief Ketamine® & Infusion Therapy was named a Top Addiction Treatment Company for 2024 by Healthcare Business Review—a recognition that underscores the impact of this novel approach.

A New Standard for the Future of Addiction Care

The launch of this program marks a turning point in how medical professionals may approach addiction treatment going forward. By integrating neuromodulation, advanced infusion therapy, trauma-informed psychological care, and concierge support, Dr. Austin Harris has created a paradigm in which recovery is not just possible but sustainable.

As the national addiction crisis continues to evolve, the methods pioneered at NeuroRelief® offer a glimpse into a future where treatment is more personalized, more scientifically sophisticated, and far more effective than what has historically been available.

In a field too often defined by hopelessness, Dr. Austin Harris brings renewed optimism—anchored in data, compassion, and a steadfast belief that recovery should be attainable for everyone.

Comments
Market Opportunity
FUTURECOIN Logo
FUTURECOIN Price(FUTURE)
$0.11858
$0.11858$0.11858
0.00%
USD
FUTURECOIN (FUTURE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Born Again’ Season 3 Way Before Season 2

Born Again’ Season 3 Way Before Season 2

The post Born Again’ Season 3 Way Before Season 2 appeared on BitcoinEthereumNews.com. Daredevil Born Again Marvel MCU fans were thrilled that Charlie Cox’s Daredevil was being brought back to life after his unceremonious execution after his show’s Netflix run, where everything was transitioning to Disney Plus. Born Again felt like a moment that would never come, and when it did, it mostly satisfied fans, with few exceptions. Now, according to a new IGN interview with head of TV Brad Winderbaum, Marvel has greenlit Daredevil: Born Again for season 3, well before season 2 airs in March 2026. Originally, the plan was an 18-episode run across two seasons, but Marvel seems to have much larger plans for Matt Murdoch and his series. This is a combination of two things. First, the positive fan reception to season 1. While there were some hiccups here, where the middle of the season had parts of the previously canned version of the show they had to work around, the first and last few episodes were incredible, and that’s the team making all of season 2 and presumably season 3 going forward. So, that’s great news. Second, this is a move by Marvel to reduce the cost of its endless supply of Disney Plus shows by focusing on more “street level” content. MCU series have been all over the place in terms of their focus and their budgets, culminating in the ridiculous $212 million budget for six episodes of the VFX-heavy Secret Invasion, one of the worst things Marvel has ever produced. Now? The name of the game is lower costs. Agatha All Along was a prime example of this, one of the MCU’s cheapest projects ever but one of its best shows. Disney is investing deeper into the “Daredevil-verse” here, as season 2 of Born Again features Jessica Jones, who might be destined to return for her…
Share
BitcoinEthereumNews2025/09/19 02:29
Unleashing A New Era Of Seller Empowerment

Unleashing A New Era Of Seller Empowerment

The post Unleashing A New Era Of Seller Empowerment appeared on BitcoinEthereumNews.com. Amazon AI Agent: Unleashing A New Era Of Seller Empowerment Skip to content Home AI News Amazon AI Agent: Unleashing a New Era of Seller Empowerment Source: https://bitcoinworld.co.in/amazon-ai-seller-tools/
Share
BitcoinEthereumNews2025/09/18 00:10
CME Group to launch Solana and XRP futures options in October

CME Group to launch Solana and XRP futures options in October

The post CME Group to launch Solana and XRP futures options in October appeared on BitcoinEthereumNews.com. CME Group is preparing to launch options on SOL and XRP futures next month, giving traders new ways to manage exposure to the two assets.  The contracts are set to go live on October 13, pending regulatory approval, and will come in both standard and micro sizes with expiries offered daily, monthly and quarterly. The new listings mark a major step for CME, which first brought bitcoin futures to market in 2017 and added ether contracts in 2021. Solana and XRP futures have quickly gained traction since their debut earlier this year. CME says more than 540,000 Solana contracts (worth about $22.3 billion), and 370,000 XRP contracts (worth $16.2 billion), have already been traded. Both products hit record trading activity and open interest in August. Market makers including Cumberland and FalconX plan to support the new contracts, arguing that institutional investors want hedging tools beyond bitcoin and ether. CME’s move also highlights the growing demand for regulated ways to access a broader set of digital assets. The launch, which still needs the green light from regulators, follows the end of XRP’s years-long legal fight with the US Securities and Exchange Commission. A federal court ruling in 2023 found that institutional sales of XRP violated securities laws, but programmatic exchange sales did not. The case officially closed in August 2025 after Ripple agreed to pay a $125 million fine, removing one of the biggest uncertainties hanging over the token. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/cme-group-solana-xrp-futures
Share
BitcoinEthereumNews2025/09/17 23:55